Uncategorized
FDA approves expanded indication for Ozurdex implant
The U.S. Food and Drug Administration has approved Ozurdex for the general patient population being treated for diabetic macular edema, Allergan announced in a press release.In June, the FDA approved Ozurdex (dexamethasone intravitreal implant 0.7 mg) for the treatment of DME in pseudophakic adult patients or patients who were scheduled for cataract surgery.